

# Albert J Czaja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4800950/publications.pdf>

Version: 2024-02-01

290  
papers

26,031  
citations

4641

85  
h-index

7333

152  
g-index

300  
all docs

300  
docs citations

300  
times ranked

7532  
citing authors

#	ARTICLE	IF	CITATIONS
1	Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4979-5005.	1.1	5
2	Examining micro-ribonucleic acids as diagnostic and therapeutic prospects in autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 591-607.	1.3	3
3	Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2493-2512.	1.1	9
4	Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	7
5	Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 3705-3733.	1.4	9
6	Review article: targeting the B cell activation system in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 902-922.	1.9	4
7	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020, 72, 671-722.	3.6	473
8	Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1286-1304.	1.9	5
9	Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. <i>Hepatology</i> , 2020, 72, 753-769.	3.6	30
10	Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination. <i>Clinical Liver Disease</i> , 2020, 15, S72-S81.	1.0	2
11	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019, 52, 144-160.	1.2	10
12	Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1449-1450.	1.9	2
13	Letter: high ferritin to haemoglobin ratio is related to early mortality in patients with alcoholic hepatitis – author’s reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1457-1458.	1.9	0
14	Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis – offender or bystander? Authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 959-960.	1.9	0
15	Letter: vitamin D deficiency and autoimmune hepatitis – from research to treatment – authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1104-1105.	1.9	0
16	Editorial: the role of vitamin D in autoimmune hepatitis – authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 343-344.	1.9	0
17	Review article: iron disturbances in chronic liver diseases other than haemochromatosis – pathogenic, prognostic, and therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 681-701.	1.9	32
18	Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 324-344.	1.1	38

#	ARTICLE	IF	CITATIONS
19	Recurrent and De Novo Autoimmune Hepatitis. Liver Transplantation, 2019, 25, 152-166.	1.3	59
20	Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 173-182.	1.9	46
21	Autoimmune Hepatitis and Immune-Mediated Cholestatic Liver Diseases. , 2019, , 251-305.		0
22	Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. World Journal of Gastroenterology, 2019, 25, 6579-6606.	1.4	23
23	Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. Digestive Diseases and Sciences, 2018, 63, 1706-1725.	1.1	13
24	Autoimmune hepatitis. Nature Reviews Disease Primers, 2018, 4, 18017.	18.1	280
25	Epigenetic changes and their implications in autoimmune hepatitis. European Journal of Clinical Investigation, 2018, 48, e12899.	1.7	30
26	Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Review of Gastroenterology and Hepatology, 2018, 12, 547-564.	1.4	18
27	Evolving paradigm of treatment for autoimmune hepatitis. Expert Review of Clinical Immunology, 2017, 13, 781-798.	1.3	12
28	Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. Gastroenterology Clinics of North America, 2017, 46, 345-364.	1.0	22
29	Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2017, 46, 920-937.	1.9	21
30	Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. Digestive Diseases and Sciences, 2017, 62, 2277-2292.	1.1	55
31	Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. World Journal of Gastroenterology, 2017, 23, 859.	1.4	51
32	Overlap Syndromes of Primary Sclerosing Cholangitis. , 2017, , 41-57.		0
33	Autoimmune Liver Diseases: Autoimmune Hepatitis. , 2017, , 217-250.		0
34	Autoimmune Liver Diseases: Overlap Syndromes. , 2017, , 307-328.		0
35	Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. World Journal of Gastroenterology, 2016, 22, 9257.	1.4	55
36	Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut and Liver, 2016, 10, 177.	1.4	124

#	ARTICLE	IF	CITATIONS
37	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 2816-2835.	2.6	451
38	Targeting Hepatic Fibrosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3118-3139.	1.1	28
39	Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2784-2803.	1.1	25
40	Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2881-2900.	1.1	51
41	Adoptive cell transfer in autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 821-836.	1.4	13
42	Letter: reversibility of hepatic fibrosis and immunosuppression withdrawal in patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 794-795.	1.9	0
43	Cell Mediators of Autoimmune Hepatitis and Their Therapeutic Implications. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1528-1542.	1.1	34
44	Diagnosis and Management of Autoimmune Hepatitis. <i>Clinics in Liver Disease</i> , 2015, 19, 57-79.	1.0	44
45	Hepatic inflammation and progressive liver fibrosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 2515.	1.4	272
46	Overlap syndromes. <i>Clinical Liver Disease</i> , 2014, 3, 2-5.	1.0	10
47	Cholestatic Phenotypes of Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1430-1438.	2.4	55
48	Letter: guidelines for the management of autoimmune hepatitis - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 115-116.	1.9	0
49	Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 385-406.	1.9	69
50	Current and prospective pharmacotherapy for autoimmune hepatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1715-1736.	0.9	35
51	Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1043-1058.	1.9	32
52	Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 261-279.	1.9	68
53	Targeting Apoptosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2890-2904.	1.1	42
54	Review article: the management of autoimmune hepatitis beyond consensus guidelines. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 343-364.	1.9	50

#	ARTICLE	IF	CITATIONS
55	Management of Recalcitrant Autoimmune Hepatitis. <i>Current Hepatitis Reports</i> , 2013, 12, 66-77.	0.3	5
56	Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1459-1476.	1.1	47
57	Acute and Acute Severe (Fulminant) Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 897-914.	1.1	110
58	Autoimmune hepatitis in diverse ethnic populations and geographical regions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 365-385.	1.4	56
59	Letter: treatment of autoimmune acute liver failure - beyond consensus guidelines; author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1144-1144.	1.9	0
60	Diagnosis and Management of the Overlap Syndromes of Autoimmune Hepatitis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2013, 27, 417-423.	1.8	60
61	Challenges in the Diagnosis and Management of Autoimmune Hepatitis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2013, 27, 531-539.	1.8	17
62	Current management strategies for hepatocellular carcinoma. <i>Minerva Gastroenterologica E Dietologica</i> , 2013, 59, 143-59.	2.2	3
63	Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II. Inflammation and Allergy: Drug Targets, 2012, 11, 351-363.	1.8	17
64	Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I. Inflammation and Allergy: Drug Targets, 2012, 11, 337-350.	1.8	17
65	Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 691-707.	1.9	59
66	Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis After Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2248-2266.	1.1	84
67	Advances in the Current Treatment of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1996-2010.	1.1	43
68	The Overlap Syndromes of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 58, 326-43.	1.1	62
69	Drug choices in autoimmune hepatitis: Part B "nonsteroids. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 617-635.	1.4	38
70	Drug choices in autoimmune hepatitis: Part A "steroids. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 603-615.	1.4	30
71	Autoimmune Hepatitis: Focusing on Treatments other than Steroids. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 615-620.	1.8	36
72	Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. <i>Liver International</i> , 2012, 32, 85-92.	1.9	70

#	ARTICLE	IF	CITATIONS
73	Autoantibody-Negative Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 610-624.	1.1	75
74	Comparability of Probable and Definite Autoimmune Hepatitis by International Diagnostic Scoring Criteria. <i>Gastroenterology</i> , 2011, 140, 1472-1480.	0.6	43
75	Autoimmune hepatitis in special patient populations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 689-700.	1.0	31
76	Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 545-554.	1.1	70
77	Drug-Induced Autoimmune-Like Hepatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 958-976.	1.1	229
78	Cryptogenic Chronic Hepatitis and Its Changing Guise in Adults. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3421-3438.	1.1	46
79	Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis. <i>Current Pharmaceutical Design</i> , 2011, 17, 3120-3140.	0.9	35
80	Emerging Opportunities for Site-Specific Molecular and Cellular Interventions in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2712-2726.	1.1	26
81	Late Relapse of Type 1 Autoimmune Hepatitis After Corticosteroid Withdrawal. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1761-1769.	1.1	33
82	Autoantibodies as Prognostic Markers in Autoimmune Liver Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2144-2161.	1.1	72
83	Diagnosis and management of autoimmune hepatitis. <i>Hepatology</i> , 2010, 51, 2193-2213.	3.6	1,243
84	Putting flesh and polish on autoimmune hepatitis and moving the disease of exclusion to inclusion. <i>Hepatology</i> , 2010, 52, 1177-1184.	3.6	2
85	Reply:. <i>Hepatology</i> , 2010, 52, 1857-1858.	3.6	3
86	Difficult treatment decisions in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2010, 16, 934.	1.4	66
87	Animal models of autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 429-443.	1.4	22
88	Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis. <i>Gastroenterology</i> , 2010, 139, 58-72.e4.	0.6	252
89	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 436-442.	3.0	123
90	Current and future treatments of autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 269-291.	1.4	53

#	ARTICLE	IF	CITATIONS
91	Special Clinical Challenges in Autoimmune Hepatitis: The Elderly, Males, Pregnancy, Mild Disease, Fulminant Onset, and Nonwhite Patients. <i>Seminars in Liver Disease</i> , 2009, 29, 315-330.	1.8	47
92	Recurrent autoimmune hepatitis after liver transplantation: A disease continuum or a fresh start?. <i>Liver Transplantation</i> , 2009, 15, 1169-1171.	1.3	26
93	Features and consequences of untreated type 1 autoimmune hepatitis. <i>Liver International</i> , 2009, 29, 816-823.	1.9	67
94	Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. <i>Journal of Hepatology</i> , 2009, 51, 161-167.	1.8	106
95	Mycophenolate mofetil to the rescue in autoimmune hepatitis: A fresh sprout on the decision tree. <i>Journal of Hepatology</i> , 2009, 51, 8-10.	1.8	17
96	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 215-222.	1.0	19
97	Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. <i>World Journal of Gastroenterology</i> , 2009, 15, 2314.	1.4	36
98	HLA DRB1*13 as a Risk Factor for Type 1 Autoimmune Hepatitis in North American Patients. <i>Digestive Diseases and Sciences</i> , 2008, 53, 522-528.	1.1	21
99	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 169-176.	3.6	1,553
100	Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 1540-1548.	3.6	179
101	Arthur Joseph McCullough, Jr., 58th President, AASLD. <i>Hepatology</i> , 2008, 47, 775-776.	3.6	0
102	Genetic Factors Affecting the Occurrence, Clinical Phenotype, and Outcome of Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 379-388.	2.4	93
103	Chapter 11 Immunopathogenesis of Autoimmune Liver Damage. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 8, 121-139.	0.1	1
104	Clinical Features, Differential Diagnosis and Treatment of Autoimmune Hepatitis in the Elderly. <i>Drugs and Aging</i> , 2008, 25, 219-239.	1.3	44
105	Predictive Factors for Hepatocellular Carcinoma in Type 1 Autoimmune Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1944-1951.	0.2	85
106	Safety issues in the management of autoimmune hepatitis. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 319-333.	1.0	97
107	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2008, 24, 298-305.	1.0	15
108	Frequency, Behavior, and Prognostic Implications of Antimitochondrial Antibodies in Type 1 Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 1047-1053.	1.1	56

#	ARTICLE	IF	CITATIONS
109	Progress in the diagnosis and treatment of autoimmune hepatitis. <i>Minerva Medica</i> , 2008, 99, 549-68.	0.3	6
110	Autoimmune hepatitis. Part A: pathogenesis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 113-128.	1.4	77
111	Autoimmune hepatitis. Part B: diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 129-143.	1.4	30
112	Autoimmune liver disease and rheumatic manifestations. <i>Current Opinion in Rheumatology</i> , 2007, 19, 74-80.	2.0	14
113	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2007, 23, 255-262.	1.0	44
114	Current therapy for autoimmune hepatitis. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 202-214.	1.7	44
115	Improving the End Point of Corticosteroid Therapy in Type 1 Autoimmune Hepatitis to Reduce the Frequency of Relapse. <i>American Journal of Gastroenterology</i> , 2007, 102, 1005-1012.	0.2	156
116	Optimizing Diagnosis From the Medical Liver Biopsy. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 898-907.	2.4	50
117	Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. <i>Hepatology</i> , 2007, 46, 1138-1145.	3.6	139
118	Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: Therapeutic brinksmanship and the point beyond salvation. <i>Liver Transplantation</i> , 2007, 13, 953-955.	1.3	73
119	A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. <i>Tissue Antigens</i> , 2007, 69, 227-235.	1.0	82
120	Consequences of treatment withdrawal in type 1 autoimmune hepatitis. <i>Liver International</i> , 2007, 27, 507-515.	1.9	104
121	Evidence of a Genetic Basis for the Different Geographic Occurrences of Liver/Kidney Microsomal Antibody Type 1 in Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2007, 52, 179-184.	1.1	26
122	Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2007, 53, 43-78.	2.2	11
123	Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: A foray across diagnostic boundaries. <i>Journal of Hepatology</i> , 2006, 44, 251-252.	1.8	41
124	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2006, 22, 234-240.	1.0	14
125	Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. <i>Liver International</i> , 2006, 26, 552-558.	1.9	35
126	Clinical significance of HLA DRB1*03?DRB1*04 in type 1 autoimmune hepatitis. <i>Liver International</i> , 2006, 26, 1201-1208.	1.9	32

#	ARTICLE	IF	CITATIONS
127	Thiopurine Methyltransferase Deficiency and Azathioprine Intolerance in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 968-975.	1.1	73
128	Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. <i>Hepatology</i> , 2006, 43, 532-538.	3.6	186
129	Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. <i>Autoimmunity</i> , 2006, 39, 341-348.	1.2	20
130	The role of autoantibodies as diagnostic markers of autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 33-48.	1.3	15
131	Chronic Hepatitis. , 2006, , 729-747.		4
132	Autoimmune hepatitis--approach to diagnosis. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 55.	0.2	11
133	Current Advances in the Treatment of Autoimmune Hepatitis. <i>Gastroenterology and Hepatology</i> , 2006, 2, 107-110.	0.2	1
134	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2005, 21, 293-299.	1.0	10
135	Empiric Therapy of Autoimmune Hepatitis With Mycophenolate Mofetil. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 819-825.	1.1	86
136	Anti-tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. <i>Liver International</i> , 2005, 25, 410-419.	1.9	19
137	Treatment challenges and investigational opportunities in autoimmune hepatitis. <i>Hepatology</i> , 2005, 41, 207-215.	3.6	89
138	Current concepts in autoimmune hepatitis. <i>Annals of Hepatology</i> , 2005, 4, 6-24.	0.6	56
139	Autoantibodies in Autoimmune Liver Disease. <i>Advances in Clinical Chemistry</i> , 2005, 40, 127-164.	1.8	48
140	Current concepts in autoimmune hepatitis. <i>Annals of Hepatology</i> , 2005, 4, 6-24.	0.6	15
141	Diverse manifestations and evolving treatments of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2005, 51, 313-33.	2.2	31
142	Nonstandard Antibodies as Prognostic Markers in Autoimmune Hepatitis. <i>Autoimmunity</i> , 2004, 37, 195-201.	1.2	55
143	Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. <i>Liver International</i> , 2004, 24, 322-329.	1.9	80
144	'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. <i>Clinical and Experimental Immunology</i> , 2004, 135, 154-158.	1.1	79

#	ARTICLE	IF	CITATIONS
145	Frequency and Significance of Antibodies to <i>Saccharomyces cerevisiae</i> in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2004, 49, 611-618.	1.1	20
146	Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. <i>Hepatology</i> , 2004, 39, 1631-1638.	3.6	116
147	Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. <i>Journal of Hepatology</i> , 2004, 40, 646-652.	1.8	220
148	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 231-240.	1.0	10
149	Autoimmune Liver Disease. , 2004, , 121-125.		6
150	Frequency and significance of antibodies to chromatin in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1658-1664.	1.1	38
151	Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. <i>Liver International</i> , 2003, 23, 116-123.	1.9	81
152	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2003, 19, 232-242.	1.0	11
153	Autoantibodies in the Diagnosis and Management of Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 315-329.	1.1	56
154	Celiac Disease-Associated Autoimmune Cholangitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 3196-3198.	0.2	26
155	Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 2051-2057.	0.2	124
156	Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 413-419.	0.2	137
157	Emerging Treatments for Autoimmune Hepatitis. <i>Inflammation and Allergy: Drug Targets</i> , 2002, 1, 317-326.	3.1	12
158	Frequency and Significance of Antibodies to Soluble Liver Antigen/Liver Pancreas in Variant Autoimmune Hepatitis. <i>Autoimmunity</i> , 2002, 35, 475-483.	1.2	52
159	Treatment of Autoimmune Hepatitis. <i>Seminars in Liver Disease</i> , 2002, 22, 365-378.	1.8	101
160	Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. <i>Gut</i> , 2002, 51, 259-264.	6.1	158
161	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 334-344.	1.0	7
162	Autoimmune Hepatitis. <i>Clinics in Liver Disease</i> , 2002, 6, xi-xii.	1.0	4

#	ARTICLE	IF	CITATIONS
163	Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. <i>Journal of Hepatology</i> , 2002, 37, 302-308.	1.8	114
164	The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. <i>Clinics in Liver Disease</i> , 2002, 6, 685-705.	1.0	97
165	Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. <i>Clinics in Liver Disease</i> , 2002, 6, 707-725.	1.0	43
166	Treatment strategies in autoimmune hepatitis. <i>Clinics in Liver Disease</i> , 2002, 6, 799-824.	1.0	57
167	Genetic bases of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2139-2150.	1.1	85
168	Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis. <i>Hepatology</i> , 2002, 35, 890-897.	3.6	148
169	Diagnosis and treatment of autoimmune hepatitis. <i>Hepatology</i> , 2002, 36, 479-497.	3.6	509
170	Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. <i>Liver Transplantation</i> , 2002, 8, 505-513.	1.3	89
171	Autoantibodies in liver disease. <i>Gastroenterology</i> , 2001, 120, 239-249.	0.6	144
172	Current Concepts in the Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis. <i>Mayo Clinic Proceedings</i> , 2001, 76, 1237-1252.	1.4	39
173	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2001, 17, 268-275.	1.0	0
174	Shared genetic risk factors in autoimmune liver disease. <i>Digestive Diseases and Sciences</i> , 2001, 46, 140-147.	1.1	51
175	Autoimmune hepatitis with incidental histologic features of bile duct injury. <i>Hepatology</i> , 2001, 34, 659-665.	3.6	174
176	Recurrent autoimmune hepatitis after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 302-310.	1.3	185
177	Understanding The Pathogenesis of Autoimmune Hepatitis. <i>American Journal of Gastroenterology</i> , 2001, 96, 1224-1231.	0.2	109
178	Autoimmune hepatitis and its variant syndromes. <i>Gut</i> , 2001, 49, 589-594.	6.1	87
179	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , 2000, 16, 262-270.	1.0	3
180	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. <i>Hepatology</i> , 2000, 31, 49-53.	3.6	233

#	ARTICLE	IF	CITATIONS
181	Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser) <sup>Sec</sup> complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. <i>Clinical and Experimental Immunology</i> , 2000, 121, 364-374.	1.1	135
182	Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. <i>Immunological Reviews</i> , 2000, 174, 250-259.	2.8	188
183	Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1028-1035.	1.1	44
184	Hepatocellular carcinoma in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1944-1948.	1.1	86
185	Autoimmune hepatitis: The investigational and clinical challenges. <i>Hepatology</i> , 2000, 31, 1194-1200.	3.6	74
186	Autoimmune cholangitis within the spectrum of autoimmune liver disease. <i>Hepatology</i> , 2000, 31, 1231-1238.	3.6	124
187	Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. <i>Gastroenterology</i> , 2000, 119, 1312-1316.	0.6	124
188	Therapy of autoimmune diseases - state of the art. , 2000, , 311-324.		0
189	Variant forms of autoimmune hepatitis. <i>Current Gastroenterology Reports</i> , 1999, 1, 63-70.	1.1	39
190	Special report: Autoimmune hepatitis. <i>Current Treatment Options in Gastroenterology</i> , 1999, 2, 423-436.	0.3	2
191	Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. <i>Hepatology</i> , 1999, 30, 851-856.	3.6	178
192	Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. <i>Hepatology</i> , 1999, 30, 1381-1386.	3.6	133
193	The immunoreactive propensity of autoimmune hepatitis: Is it corticosteroid-dependent after liver transplantation?. <i>Liver Transplantation</i> , 1999, 5, 460-463.	1.9	28
194	Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. <i>Journal of Hepatology</i> , 1999, 30, 394-401.	1.8	173
195	International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. <i>Journal of Hepatology</i> , 1999, 31, 929-938.	1.8	2,681
196	Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , 1999, 117, 645-652.	0.6	163
197	Drug Therapy in the Management of Type 1 Autoimmune Hepatitis. <i>Drugs</i> , 1999, 57, 49-68.	4.9	66
198	Viral Genotypes as Determinants of Autoimmune Expression in Chronic Hepatitis C. <i>Mayo Clinic Proceedings</i> , 1999, 74, 454-460.	1.4	18

#	ARTICLE	IF	CITATIONS
199	Immune phenotype of chronic liver disease. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2149-2155.	1.1	63
200	Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1998, 43, 1725-1731.	1.1	23
201	Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. <i>Digestive Diseases and Sciences</i> , 1998, 43, 1322-1331.	1.1	32
202	Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2190-2195.	1.1	158
203	Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 483-489.	1.4	36
204	Frequency and nature of the variant syndromes of autoimmune liver disease. <i>Hepatology</i> , 1998, 28, 360-365.	3.6	328
205	Host- and disease-specific factors affecting steatosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 1998, 29, 198-206.	1.8	227
206	GB Virus-C Infection in Type 1 Autoimmune Hepatitis. <i>Mayo Clinic Proceedings</i> , 1998, 73, 412-418.	1.4	7
207	GB virus-C infection in type 1 autoimmune hepatitis.. <i>Mayo Clinic Proceedings</i> , 1998, 73, 412-418.	1.4	7
208	Extrahepatic Immunologic Features of Chronic Viral Hepatitis. <i>Digestive Diseases</i> , 1997, 15, 125-144.	0.8	37
209	Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. <i>Gastroenterology</i> , 1997, 112, 2028-2035.	0.6	257
210	Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1688-1696.	1.1	78
211	Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. <i>Hepatology</i> , 1997, 25, 317-323.	3.6	255
212	Histological findings in chronic hepatitis C with autoimmune features. <i>Hepatology</i> , 1997, 26, 459-466.	3.6	90
213	Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. <i>Hepatology</i> , 1997, 26, 567-572.	3.6	89
214	Recurrence of nonalcoholic steatohepatitis after liver transplantation. <i>Liver Transplantation</i> , 1997, 3, 185-186.	1.9	31
215	Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. <i>Hepatology</i> , 1997, 26, 567-572.	3.6	9
216	Genetic distinctions between types 1 and 2 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , 1997, 92, 2197-200.	0.2	62

#	ARTICLE	IF	CITATIONS
217	DIAGNOSIS AND THERAPY OF AUTOIMMUNE LIVER DISEASE. <i>Medical Clinics of North America</i> , 1996, 80, 973-994.	1.1	46
218	Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , 1996, 110, 848-857.	0.6	287
219	Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. <i>Journal of Hepatology</i> , 1996, 24, 52-59.	1.8	106
220	The Variant Forms of Autoimmune Hepatitis. <i>Annals of Internal Medicine</i> , 1996, 125, 588.	2.0	196
221	Validation of scoring system for diagnosis of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 305-314.	1.1	128
222	Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1733-1740.	1.1	63
223	Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. <i>Hepatology</i> , 1996, 24, 1068-1073.	3.6	190
224	Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. <i>Hepatology</i> , 1996, 24, 1068-1073.	3.6	18
225	Biopsy Findings and Clinical Correlations. <i>American Journal of Surgical Pathology</i> , 1995, 19, 699-708.	2.1	108
226	Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2098-2106.	1.1	31
227	Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 33-40.	1.1	38
228	Autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 435-456.	1.1	154
229	5 Autoantibodies. <i>Bailliere's Clinical Gastroenterology</i> , 1995, 9, 723-744.	0.9	20
230	Immunologic features and HLA associations in chronic viral hepatitis. <i>Gastroenterology</i> , 1995, 108, 157-164.	0.6	128
231	High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. <i>Gastroenterology</i> , 1995, 108, 1159-1166.	0.6	181
232	Frequency and significance of antibodies to histones in autoimmune hepatitis. <i>Journal of Hepatology</i> , 1995, 23, 32-38.	1.8	57
233	The validity and importance of subtypes in autoimmune hepatitis: a point of view. <i>American Journal of Gastroenterology</i> , 1995, 90, 1206-11.	0.2	142
234	The nature and prognostic implications of autoimmune hepatitis with an acute presentation. <i>Journal of Hepatology</i> , 1994, 21, 866-871.	1.8	159

#	ARTICLE	IF	CITATIONS
235	Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. <i>Gastroenterology</i> , 1994, 107, 200-207.	0.6	120
236	Autoimmune hepatitis and viral infection. <i>Gastroenterology Clinics of North America</i> , 1994, 23, 547-66.	1.0	13
237	Genetic predispositions for the immunological features of chronic active hepatitis. <i>Hepatology</i> , 1993, 18, 816-822.	3.6	122
238	Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. <i>Journal of Hepatology</i> , 1993, 18, 342-352.	1.8	114
239	Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. <i>Journal of Hepatology</i> , 1993, 17, 180-186.	1.8	25
240	Chronic Active Hepatitis: The Challenge for a New Nomenclature. <i>Annals of Internal Medicine</i> , 1993, 119, 510.	2.0	63
241	Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. <i>Gastroenterology</i> , 1993, 105, 1824-1832.	0.6	297
242	The nature and prognosis of severe cryptogenic chronic active hepatitis. <i>Gastroenterology</i> , 1993, 104, 1755-1761.	0.6	108
243	Significance of HLA DR4 in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , 1993, 105, 1502-1507.	0.6	198
244	Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. <i>Gastroenterology</i> , 1993, 105, 1522-1528.	0.6	150
245	Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. <i>Gastroenterology</i> , 1992, 103, 1290-1295.	0.6	205
246	Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. <i>Gastroenterology</i> , 1992, 102, 1675-1679.	0.6	18
247	Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. <i>Journal of Hepatology</i> , 1992, 14, 88-93.	1.8	28
248	Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. <i>Journal of Hepatology</i> , 1992, 14, 325-331.	1.8	157
249	Sequential histologic evaluations in collagenous colitis. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1903-1909.	1.1	158
250	Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. <i>Hepatology</i> , 1992, 15, 215-221.	3.6	187
251	Frequency and Significance of Antibody to Hepatitis C Virus in Severe Corticosteroid-Treated Autoimmune Chronic Active Hepatitis. <i>Mayo Clinic Proceedings</i> , 1991, 66, 572-582.	1.4	35
252	Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Gastroenterology</i> , 1990, 98, 1587-1593.	0.6	58

#	ARTICLE	IF	CITATIONS
253	Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. <i>Hepatology</i> , 1990, 11, 1044-1049.	3.6	73
254	Clinical Features and Prognostic Implications of Severe Corticosteroid-Treated Cryptogenic Chronic Active Hepatitis. <i>Mayo Clinic Proceedings</i> , 1990, 65, 23-30.	1.4	57
255	Frequency and Significance of Antibody to Hepatitis C Virus in Severe Corticosteroid-Treated Cryptogenic Chronic Active Hepatitis. <i>Mayo Clinic Proceedings</i> , 1990, 65, 1303-1313.	1.4	28
256	Autoimmune chronic active hepatitis: A specific entity? The negative argument*. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1990, 5, 343-351.	1.4	33
257	The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. <i>Hepatology</i> , 1989, 9, 193-197.	3.6	124
258	Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Hepatology</i> , 1989, 10, 39-43.	3.6	74
259	Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: A retrospective analysis. <i>Gastroenterology</i> , 1989, 97, 1288-1293.	0.6	33
260	Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Hepatology</i> , 1988, 8, 1679-1683.	3.6	80
261	Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Gastroenterology</i> , 1988, 95, 448-453.	0.6	125
262	Diagnosis and management of chronic active hepatitis B. <i>Comprehensive Therapy</i> , 1988, 14, 46-53.	0.2	0
263	Frequency and significance of serum $\alpha$ -fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , 1987, 93, 687-692.	0.6	17
264	Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , 1987, 92, 215-219.	0.6	89
265	Frequency and significance of antibody to double-stranded DNA in chronic active hepatitis. <i>Hepatology</i> , 1986, 6, 976-980.	3.6	29
266	Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. <i>Digestive Diseases and Sciences</i> , 1986, 31, 705-711.	1.1	109
267	How lupoid is lupoid hepatitis?. <i>Journal of Rheumatology</i> , 1986, 13, 95-8.	1.0	21
268	Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , 1984, 87, 1222-1227.	0.6	85
269	Natural History, Clinical Features, and Treatment of Autoimmune Hepatitis. <i>Seminars in Liver Disease</i> , 1984, 4, 1-12.	1.8	157
270	Complete Resolution of Inflammatory Activity Following Corticosteroid Treatment of HBsAg-Negative Chronic Active Hepatitis. <i>Hepatology</i> , 1984, 4, 622-627.	3.6	164

#	ARTICLE	IF	CITATIONS
271	Correspondence. Liver Blood Flow Using Clearance Techniques. <i>Hepatology</i> , 1984, 4, 746-748.	3.6	0
272	Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. <i>Liver</i> , 1984, 4, 105-116.	0.1	113
273	Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , 1984, 87, 1222-7.	0.6	16
274	Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. <i>Gastroenterology</i> , 1983, 85, 713-717.	0.6	151
275	Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. <i>Gastroenterology</i> , 1983, 85, 713-7.	0.6	29
276	Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , 1982, 57, 303-9.	1.4	30
277	Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: Correlation of serum transaminase and gamma globulin levels with histologic features. <i>Gastroenterology</i> , 1981, 80, 687-692.	0.6	133
278	Corticosteroid-Treated Chronic Active Hepatitis in Remission. <i>New England Journal of Medicine</i> , 1981, 304, 5-9.	13.9	130
279	Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. <i>Gastroenterology</i> , 1981, 80, 687-92.	0.6	28
280	Current problems in the diagnosis and management of chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , 1981, 56, 311-23.	1.4	18
281	Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. <i>Gastroenterology</i> , 1980, 78, 518-523.	0.6	128
282	Systemic mycosis complicating high dose corticosteroid treatment of chronic active liver disease. <i>American Journal of Gastroenterology</i> , 1980, 74, 428-32.	0.2	14
283	Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. <i>Gastroenterology</i> , 1980, 78, 518-23.	0.6	23
284	Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. <i>Mayo Clinic Proceedings</i> , 1980, 55, 360-4.	1.4	32
285	Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. <i>Gastroenterology</i> , 1979, 77, 629-633.	0.6	39
286	Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. <i>Gastroenterology</i> , 1979, 77, 629-33.	0.6	9
287	Malignancy in Chronic Liver Disease. <i>Gastroenterology</i> , 1977, 73, 192-193.	0.6	11
288	Severe chronic active liver disease. <i>The American Journal of Digestive Diseases</i> , 1977, 22, 973-980.	0.9	83

#	ARTICLE	IF	CITATIONS
289	Malignancy in chronic liver disease. <i>Gastroenterology</i> , 1977, 73, 192-3.	0.6	1
290	Epigenetic Aspects and Prospects in Autoimmune Hepatitis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6